From GlobeNewswire:

Cogent Biosciences, Inc. has secured a private investment in public equity financing deal, resulting in gross proceeds of approximately $225 million. This funding will help fund ongoing clinical trials, including SUMMIT, PEAK, and APEX. The company plans to sell 17 million shares of common stock at $7.50 per share. The private placement, expected to close on February 16, 2024, will help fund research and development activities for bezuclastinib. Cogent intends to use the proceeds to fund operations until 2027. They will host a webcast on February 23, 2024, to review SUMMIT Part 1b data.



Read more at GlobeNewswire: Cogent Biosciences Announces Oversubscribed $225 Million